Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
– Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 –
– Revenue covenant reduced to $125 million –
– Term loan annual interest expense projected to be reduced by ~70% –
Related news for (CHRS)
- Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals for up to $558M
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium